Ibrutinib Plus Rituximab Demonstrate Efficacy in Phase 2 Trial of MCL
Preetesh Jain, MD, PhD, discusses the efficacy and predictors of response with ibrutinib and rituximab in combination as treatment of patients with previously untreated mantle cell lymphoma.